Aufklappen
Schliessen
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
| Leser | Medien | |
|---|---|---|---|---|
| 15.07. | Jaguar Health, Inc. - 8-K, Current Report | - | SEC Filings | |
► Artikel lesen | ||||
| 15.07. | Jaguar Health files for equity offering; shares down 8% premarket | 11 | Seeking Alpha | |
► Artikel lesen | ||||
| 15.07. | Jaguar Health, Inc.: Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million | 10 | ACCESSWIRE | |
| Maturity Date of Remaining Merger-related Debt is December 31, 2020
SAN FRANCISCO, CA / ACCESSWIRE / July 15, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage... ► Artikel lesen | ||||
| Börsennews zur JAGUAR HEALTH Aktie und weiteren Hot Stocks erhalten | LYNX | |||
► Artikel lesen | ||||
| 15.07. | Jaguar Health, Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | |
► Artikel lesen | ||||
| 11.07. | Jaguar Health's Wholly Owned Subsidiary, Napo Pharmaceuticals, Inc., Commits to Support Study Evaluating the Effect of Crofelemer on Patients With Chronic Idiopathic Diarrhea | 7 | ACCESSWIRE | |
| SAN FRANCISCO, CA / ACCESSWIRE / July 11, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived... ► Artikel lesen | ||||
| 05.07. | Jaguar Health, Inc. - S-1/A, General form for registration of securities | 5 | SEC Filings | |
► Artikel lesen | ||||
| 05.07. | Jaguar Health, Inc. - 8-K, Current Report | 5 | SEC Filings | |
► Artikel lesen | ||||
| 28.06. | Jaguar Health reduces debt to $5.7M; shares up 7% premarket | 6 | Seeking Alpha | |
► Artikel lesen | ||||
| 28.06. | Jaguar Health, Inc.: Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $5.7 Million | 10 | ACCESSWIRE | |
| Maturity Date of Remaining Merger-related Debt is December 31, 2020
SAN FRANCISCO, CA / ACCESSWIRE / June 28, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage... ► Artikel lesen | ||||
| 26.06. | Jaguar Health, Inc.: Jaguar Health Engages Integrium, LLC to Support Clinical Study Evaluating the Effect of Mytesi on the Microbiome | 12 | ACCESSWIRE | |
| Study will Examine the Possible Benefits of Mytesi on Gut Health, Including Bloating and Abdominal Discomfort, in People Living with HIV
SAN FRANCISCO, CA / ACCESSWIRE / June 26, 2019 / Jaguar Health... ► Artikel lesen | ||||
| 25.06. | Jaguar Health Says It Has Regained Nasdaq Compliance | 1 | Benzinga.com | |
► Artikel lesen | ||||
| 25.06. | Jaguar Health, Inc. - 8-K, Current Report | 4 | SEC Filings | |
► Artikel lesen | ||||
| 25.06. | Jaguar Health, Inc.: Jaguar Health Regains Compliance with All Applicable Nasdaq Stock Market Listing Standards | 11 | ACCESSWIRE | |
| SAN FRANCISCO, CA / ACCESSWIRE / June 24, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived... ► Artikel lesen | ||||
| 20.06. | Arbutus Biopharma leads healthcare gainers; Verastem and Jaguar Health among losers | 21 | Seeking Alpha | |
► Artikel lesen | ||||
| 19.06. | Jaguar Health reports findings for final Canalevia technical section for CID in dogs | 1 | Seeking Alpha | |
► Artikel lesen | ||||
| 19.06. | Jaguar Health, Inc.: Jaguar Health Announces Key Finding for Final Canalevia Technical Section for Proposed Indication of Chemotherapy-Induced Diarrhea in Dogs | 8 | ACCESSWIRE | |
| Target Animal Safety Study Results Indicate Canalevia NOAEL (No-Observed-Adverse-Effect Level) is Approximately Six Times Greater than Previously Demonstrated and that Canalevia is Also Safe for Use... ► Artikel lesen | ||||
| 18.06. | Jaguar Health, Inc.: Jaguar Health Announces Completion of Pilot Study in Dogs in Support of Future Clinical Investigations Evaluating Crofelemer for Treatment of Noninfectious Diarrhea in Human Cancer Patients Receiving Tyrosine Kinase Inhibitors | 11 | ACCESSWIRE | |
| SAN FRANCISCO, CA / ACCESSWIRE / June 18, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived... ► Artikel lesen | ||||
| 14.06. | Jaguar Health, Inc. - 8-K, Current Report | 4 | SEC Filings | |
► Artikel lesen | ||||
| 12.06. | Jaguar Health, Inc. - S-1, General form for registration of securities | 2 | SEC Filings | |
► Artikel lesen | ||||
| 12.06. | 5 Top Gainers In Healthcare Sector (JAGX, CTRV, ZYNE...) | 13 | AFX News | |
| WASHINGTON (dpa-AFX) - The following are some of today's top gainers in the pharma/biotech sector.1. Jaguar Health Inc. (JAGX)Jaguar Health is a commercial-stage pharmaceutical company focused... ► Artikel lesen | ||||
Seite:
1 2 3 4 Weiter >>
78 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten:
VerkaufenHaltenKaufen
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | |
|---|---|---|---|---|
| BAYER | 61,31 | +2,87 % | Bayer-AR Hoffmann erwartet keine Vergleiche bei Glyphosat-Klagen | |
| FRANKFURT (Dow Jones)--Reiner Hoffmann, Chef des Deutschen Gewerkschaftsbunds und Aufsichtsrat bei Bayer, rechnet nicht mit schnellen Vergleichen bei den Glyphosat-Klagen. "Bayer bleibt dabei... ► Artikel lesen | ||||
| NOVARTIS | 84,62 | +0,59 % | Guten Morgen mit Bayer, WireCard, Leoni, Novartis ... | |
| BAYER - 'HB': STAATSANWALTSCHAFT ERMITTELT WEGEN IBEROGAST Bayer -AR Hoffmann erwartet keine Vergleiche bei Glyphosat-Klagen Hapag-Lloyd sieht sich trotz Handelsstreit im laufenden Jahr auf Kurs (EamS)... ► Artikel lesen | ||||
| NOVO NORDISK | 43,06 | -0,06 % | NOVO NORDISK A S - 6-K, Report of foreign issuer | |
► Artikel lesen | ||||
| MERCK KGAA | 96,72 | +2,41 % | Merck und Broad Institute geben CRISPR-Lizenzvereinbarung zur Förderung von Innovationen bekannt | |
| - Neues Rahmenwerk vereinfacht und beschleunigt Zugang zu geistigem Eigentum an CRISPR für Forschungszwecke Darmstadt, Deutschland (ots/PRNewswire) - Merck" veröffentlicht. Merck hat mit dem Merck... ► Artikel lesen | ||||
| PFIZER | 38,40 | +1,05 % | IRW-News: ICC International Cannabis Corp: Dr. Alex Makriyannis, PhD, Berater von Pfizer, Bristol-Myers Squibb und Biogen, unterstützt einen von ICC finanzierten Biosynthese-Cannabinoid-Spezialisten als ... | |
| IRW-PRESS: ICC International Cannabis Corp: Dr. Alex Makriyannis,
PhD, Berater von Pfizer, Bristol-Myers Squibb und Biogen,
unterstützt einen von ICC finanzierten
Biosynthese-Cannabinoid-Spezialisten... ► Artikel lesen | ||||
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und mit der Push-Technologie von
Nachrichten • Aktienkurse • DAX • Xetra-Orderbuch • Watchlist
Ad hoc-Mitteilungen • Nachrichten Börsen • Aktien-Empfehlungen
Branchen • Medien • Nachrichten-Archiv
Impressum | AGB | Disclaimer | Datenschutz • Presse • Mediadaten
RSS-News von FinanzNachrichten.de kostenlos für Ihren Browser und Ihre Homepage
